PharmaShots | Incisive News in 3 Shots

Subscribe Now

Hypertrophic Cardiomyopathy

MyoKardia's Mavacamten Receives the US FDA's Breakthrough Therapy Designation for Symptomatic Patients with Obstructive Hypertrophic Cardiomyopathy

MyoKardia's Mavacamten Receives the US FDA's Breakthrough Therapy Designation for Symptomatic Patients with Obstructive Hypertroph...

July 23, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us